arrow
L

Lijun Sun

Capital Medical University
H指数:18
被引数:1,650

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial
2024-01-175
OA
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naive HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96

艾诺韦林与依法韦仑联合治疗与拉米夫定/替诺福韦酯富马酸治疗初治HIV-1-positive成人药物的疗效和安全性: 48周随机对照3期临床试验的结果,随后开放标签设置,直到96周

2023-07-0111
OAAI
(5R)-5-hydroxytriptolide for HIV immunological non- responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study

(5R)-5-羟基雷公藤内酯用于接受ART的HIV免疫无反应者: 一项随机,双盲,安慰剂对照的II期研究

2023-05-0111
OAAI
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study
2022-09-0111
PRE
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
2020-12-2035
OAAI